Daktari.jpg
FA info icon.svg Angle down icon.svg Medical equipment data
Health topic HIV/AIDS
Health classification Diagnosis
FA info icon.svg Angle down icon.svg Project data
Location Massachusetts, United States
Status Clinical trial
Made No
Replicated No
OKH Manifest Download

Problem being addressed[edit | edit source]

There is a need to develop CD4 counters that do not rely on laboratory workers and expensive/complicated equipment. A counter that can be used by rural clinicians in the field without extensive training would greatly assist in managing HIV in rural areas.

Detailed description of the solution[edit | edit source]

Microfluidic cell chromatography isolates cells and other particles in a miniature sensing chamber, without the complex manual steps of blood tests. The system takes advantage of electrochemical sensing, using lysate impedance spectroscopy. The system uses a simple sensor that counts the captured CD4 cells by measuring their internal contents electrically. A hand-held instrument interprets the electrical signal, and reports the CD4 count within minutes.

Designed by[edit | edit source]

  • Designed by: Daktari Diagnostics
  • Manufacturer location: Cambridge, Massachusetts, USA

When and where it was tested/implemented[edit | edit source]

A clinical trial took place in Seattle the summer of 2010 and clinical trials have also been conducted in Uganda.

Funding Source[edit | edit source]

Funded privately and through the Gates Foundation.

References[edit | edit source]

Externally generated reports[edit | edit source]

McBride R. (2009.) Daktari Diagnostics, backed by Gates Foundation, raises funds for HIV test study. Link available here

FA info icon.svg Angle down icon.svg Page data
Part of Global Health Medical Device Compendium
SDG SDG03 Good health and well-being, SDG09 Industry innovation and infrastructure
Authors Eva Shiu
License CC-BY-SA-3.0
Language English (en)
Related 0 subpages, 3 pages link here
Impact 159 page views (more)
Created January 13, 2012 by Eva Shiu
Last modified November 22, 2022 by Irene Delgado
Cookies help us deliver our services. By using our services, you agree to our use of cookies.